The top three cancer types with genetic alteration of METTL2B is Uterine Corpus Endometrial Carcinoma (5%), Skin Cutaneous Melanoma (2%), and Ovarian serous cystadenocarcinoma (4%) (Fig. 4b). Here, METTL2B is linked to cutaneous melanoma.